bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Individual cases from historical control datasets.
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Individual patients with H3K27M-mutant DMG treated with ONC201.
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

ONC201 dosage chart for patients younger than 18 years of age.
Table S15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

GSEA analysis of genes with significantly increased H3K27me3 in ONC201-treated versus untreated patients.
Table S14 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

GSEA analysis of genes with significantly lower H3K27ac at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
Table S12 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Results of pathway impact analysis after performing integrated RNA-seq and metabolomics analysis using MetaboAnalyst.
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
Figure 4 from STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
Authors: Buckbinder Leonard , St. Jean David J. , Tieu Trang , Ladd Brendon , Hilbert Brendan , Wang Weixue , Alltucker Jacob T. , Manimala Samantha , Kryukov Gregory V. , Brooijmans Natasja , Dowdell Gregory , Jonsson Philip , Huff Michael , Guzman-Perez Angel , Jackson Erica L. , Goncalves Marcus D. , Stuart Darrin D.
Published: November 2023

Efficacy and PK/PD profiling of STX-478 and alpelisib in CAL-33 xenograft tumors. A and B, CAL-33 xenograft tumors were established in female BALB/c nude mice. Animals were randomized into treatment groups (n = 6) at approximately 160 mm3 and treated as indicated. Tumor (A) and body weight (BW; B) were measured 2×/week with group mean and standard error mean (SEM) shown. C and D, Mice bearing CAL-33 tumors were treated with oral (p.o) daily dosing of indicated treatment for 3 days, and serum insulin (C) and blood glucose (D) were measured, with individual values, group mean, and SEM shown with each treatment group compared with the vehicle group using ordinary one-way ANOVA and Dunnett multiple comparisons tests. E, pAKT (S473) was measured by Western blot in all CAL-33 tumors from mice in the 28-day efficacy study (30 and 100 mg/kg dose groups) and 3-day PK/PD study (30, 100, and 300 mg/kg dose groups). pAKT (S473) and total AKT were measured in CAL-33 tumors by Western blot. The normalized pAKT (S473) levels were plotted against the unbound concentration (red). For reference, the in vitro pAKT dose response in CAL-33 cells (orange curve) has been added (as in Fig. 2). F, pAKT levels in CAL-33 tumors showing only 100 mg/kg STX-478 and 50 mg/kg alpelisib over time. G, pAKT (S473) was measured by Western blot from the gastrocnemius of mice represented in E and F. Significance was measured using ordinary one-way ANOVA and Dunnett multiple comparisons tests. H,N = 4 mice were fasted for 4 hours and then administered vehicle, alpelisib (50 mg/kg), or STX-478 (100 mg/kg), followed 1 hour later with p.o. administration of [U-13C]-glucose. After 30 minutes, the tissues were collected and analyzed by mass spectrometry. The abundance of labeled [M+4] succinic acid (S), fumaric acid (F), and malic acid (M) in tumor and gastrocnemius is shown. Individual values, group mean, and standard error mean are shown with each treatment group compared with the vehicle group using two-way ANOVA and Holm–Šídák posttest. I, Plasma insulin was measured immediately before and 30 minutes after labeled-glucose administration.
Figure 2 from STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
Authors: Buckbinder Leonard , St. Jean David J. , Tieu Trang , Ladd Brendon , Hilbert Brendan , Wang Weixue , Alltucker Jacob T. , Manimala Samantha , Kryukov Gregory V. , Brooijmans Natasja , Dowdell Gregory , Jonsson Philip , Huff Michael , Guzman-Perez Angel , Jackson Erica L. , Goncalves Marcus D. , Stuart Darrin D.
Published: November 2023

Assessment of STX-478 mutant selectivity by profiling target engagement and functional activity in cellular assays. A, pAKT inhibition dose–response curves (HTRF assay) in MCF10A isogenic cell lines. B, Representative pAKT inhibition dose–response curves (HTRF assay). C, Correlation plot comparing alpelisib and STX-478 potency (pAKT HTRF assay) in a panel of kinase-domain mutant cell lines (orange dots) and WT PI3Kα SKBR3 (black dots) described in Supplementary Table S1. D, Correlation plot of alpelisib and STX-478 comparing pAKT IC50 at 1 hour and viability [CellTiter-Glo (CTGlo)] GI50 at 72 hours across the indicated panel of cell lines. E, Sensitivity of cancer cell lines to STX-478 and alpelisib grouped by cancer type and PIK3CA and PTEN mutational status. Screening was performed by the Broad Institute using the PRISM platform. F, Two-hour glucose uptake in primary human adipocytes as indicated in the bar graph (percent vehicle response). Seventy-two-hour viability data in H1047R PI3Kα-mutant T47D cell line are overlaid in the orange dose–response curve for comparison.
Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Protocol for NCT03134131, ONC201-018: Expanded Access to ONC201 for Patients with H3K27M-mutant and/or Midline High Grade Gliomas.
Supplementary Data S1 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: November 2023

Protocol for NCT03416530, ONC201-014: ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3K27M Gliomas.
Supplementary Figure S7 from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J. David , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Jänne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: November 2023

Supplemental pharmacodynamic effects of MRTX1719 in patients
Supplementary Figure S4 from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J. David , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Jänne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: November 2023

Supplemental in vivo pharmacodynamic characterization of MRTX1719
Supplementary Table S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Authors: Zhao Liwei , Liu Peng , Mao Misha , Zhang Shuai , Bigenwald Camille , Dutertre Charles-Antoine , Lehmann Christian H.K. , Pan Hui , Paulhan Nicolas , Amon Lukas , Buqué Aitziber , Yamazaki Takahiro , Galluzzi Lorenzo , Kloeckner Benoit , Silvin Aymeric , Pan Yuhong , Chen Hui , Tian Ai-Ling , Ly Pierre , Dudziak Diana , Zitvogel Laurence , Kepp Oliver , Kroemer Guido
Published: November 2023

Supplementary Table S3 contains the list of genes that are significantly upregulated by both BCL2 inhibitor and Bcl2 knockout, as well as their link to the Type 1 IFN responses
Supplementary Figure S9 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Authors: Zhao Liwei , Liu Peng , Mao Misha , Zhang Shuai , Bigenwald Camille , Dutertre Charles-Antoine , Lehmann Christian H.K. , Pan Hui , Paulhan Nicolas , Amon Lukas , Buqué Aitziber , Yamazaki Takahiro , Galluzzi Lorenzo , Kloeckner Benoit , Silvin Aymeric , Pan Yuhong , Chen Hui , Tian Ai-Ling , Ly Pierre , Dudziak Diana , Zitvogel Laurence , Kepp Oliver , Kroemer Guido
Published: November 2023

Supplementary Figure S9 shows the migration arrest of cDC1 by CD11b blocking antibody, as well as the effects of T cell depletion or CD11b blockade on BCL2 inhibitor-mediated control of fibrosarcomas.
Supplementary Figure S4 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Authors: Zhao Liwei , Liu Peng , Mao Misha , Zhang Shuai , Bigenwald Camille , Dutertre Charles-Antoine , Lehmann Christian H.K. , Pan Hui , Paulhan Nicolas , Amon Lukas , Buqué Aitziber , Yamazaki Takahiro , Galluzzi Lorenzo , Kloeckner Benoit , Silvin Aymeric , Pan Yuhong , Chen Hui , Tian Ai-Ling , Ly Pierre , Dudziak Diana , Zitvogel Laurence , Kepp Oliver , Kroemer Guido
Published: November 2023

Supplementary Figure S4 shows the weak cancer cell apoptosis triggered by BCL2 inhibitors, and the increased expression of immune checkpoint markers on T cells from BCL2 inhibitor-treated cancer-bearing mice.
Supplementary Figure S3 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance
Authors: Zhao Liwei , Liu Peng , Mao Misha , Zhang Shuai , Bigenwald Camille , Dutertre Charles-Antoine , Lehmann Christian H.K. , Pan Hui , Paulhan Nicolas , Amon Lukas , Buqué Aitziber , Yamazaki Takahiro , Galluzzi Lorenzo , Kloeckner Benoit , Silvin Aymeric , Pan Yuhong , Chen Hui , Tian Ai-Ling , Ly Pierre , Dudziak Diana , Zitvogel Laurence , Kepp Oliver , Kroemer Guido
Published: November 2023

Supplementary Figure S3 shows the increased DC maturation and activation upon BCL2 inhibition, and indicates that this effect is crucial for the enhancement of DC antigen cross presentation by BCL2 inhibitors.
Data from Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer
Authors: Grillo Giacomo , Keshavarzian Tina , Linder Simon , Arlidge Christopher , Mout Lisanne , Nand Ankita , Teng Mona , Qamra Aditi , Zhou Stanley , Kron Ken J. , Murison Alex , Hawley James R. , Fraser Michael , van der Kwast Theodorus H. , Raj Ganesh V. , He Housheng Hansen , Zwart Wilbert , Lupien Mathieu
Published: November 2023

Abstract
Transposable elements hold regulatory functions that impact cell fate determination by controlling gene expression. However, little is known about the transcriptional machinery engaged at transposable elements in pluripotent and mature versus oncogenic cell states. Through positional analysis over repetitive DNA sequences of H3K27ac chromatin immunoprecipitation sequencing data from 32 normal cell states, we report pluripotent/stem and mature cell state–specific “regulatory transposable elements.” Pluripotent/stem elements are binding sites for pluripotency factors (e.g., NANOG, SOX2, OCT4). Mature cell elements are docking sites for lineage-specific transcription factors, including AR and FOXA1 in prostate epithelium. Expanding the analysis to prostate tumors, we identify a subset of regulatory transposable elements shared with pluripotent/stem cells, including Tigger3a. Using chromatin editing technology, we show how such elements promote prostate cancer growth by regulating AR transcriptional activity. Collectively, our results suggest that oncogenesis arises from lineage-specific transcription factors hijacking pluripotent/stem cell regulatory transposable elements.
Significance:
We show that oncogenesis relies on co-opting transposable elements from pluripotent stem cells as regulatory elements altering the recruitment of lineage-specific transcription factors. We further discover how co-option is dependent on active chromatin states with important implications for developing treatment options against drivers of oncogenesis across the repetitive DNA.

This article is featured in Selected Articles from This Issue, p. 2293
Data from Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications
Authors: Weigelt Britta , Marra Antonio , Selenica Pier , Rios-Doria Eric , Momeni-Boroujeni Amir , Berger Michael F. , Arora Kanika , Nemirovsky David , Iasonos Alexia , Chakravarty Debyani , Abu-Rustum Nadeem R. , Da Cruz Paula Arnaud , Dessources Kimberly , Ellenson Lora H. , Liu Ying L. , Aghajanian Carol , Brown Carol L.
Published: November 2023

Abstract
Although the incidence of endometrial carcinoma (EC) is similar in Black and White women, racial disparities are stark, with the highest mortality rates observed among Black patients. Here, analysis of 1,882 prospectively sequenced ECs using a clinical FDA-authorized tumor–normal panel revealed a significantly higher prevalence of high-risk histologic and molecular EC subtypes in self-identified Black (n = 259) compared with White (n = 1,623) patients. Clinically actionable alterations, including high tumor mutational burden/microsatellite instability, which confer benefit from immunotherapy, were less frequent in ECs from Black than from White patients. Ultramutated POLE molecular subtype ECs associated with favorable outcomes were rare in Black patients. Results were confirmed by genetic ancestry analysis. CCNE1 gene amplification, which is associated with aggressive clinical behavior, was more prevalent in carcinosarcomas occurring in Black than in White patients. ECs from Black and White patients display important differences in their histologic types, molecular subtypes, driver genetic alterations, and therapeutic targets.
Significance:
Our comprehensive analysis of prospectively clinically sequenced ECs revealed significant differences in their histologic and molecular composition and in the presence of therapeutic targets in Black versus White patients. These findings emphasize the importance of incorporating diverse populations into molecular studies and clinical trials to address EC disparities.

This article is featured in Selected Articles from This Issue, p. 2293
Supplementary Figure 5 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
Authors: Tabasum Saba , Thapa Dinesh , Giobbie-Hurder Anita , Weirather Jason L. , Campisi Marco , Schol Pieter J. , Li Xiaoyu , Li Jingjing , Yoon Charles H. , Manos Michael P. , Barbie David A. , Hodi F. Stephen
Published: November 2023

Molecular validation data.
Supplementary Figure 4 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
Authors: Tabasum Saba , Thapa Dinesh , Giobbie-Hurder Anita , Weirather Jason L. , Campisi Marco , Schol Pieter J. , Li Xiaoyu , Li Jingjing , Yoon Charles H. , Manos Michael P. , Barbie David A. , Hodi F. Stephen
Published: November 2023

Volcano plots for EDIL3, MFGE8 and CTNNB1, with each spot representing Kendall rank correlation for dysfunction or exclusion across TCGA tumor types.
Supplementary Figure 2 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
Authors: Tabasum Saba , Thapa Dinesh , Giobbie-Hurder Anita , Weirather Jason L. , Campisi Marco , Schol Pieter J. , Li Xiaoyu , Li Jingjing , Yoon Charles H. , Manos Michael P. , Barbie David A. , Hodi F. Stephen
Published: November 2023

Longitudinal analysis of EDIL3 antibody response to Ipi-Bev treatment in metastatic melanoma patients.
Supplementary Figure 7 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
Authors: Zhang Caimei , Kadu Siddhant , Xiao Yansen , Johnson Omar , Kelly Andre , O'Connor Roddy S. , Lai Meizan , Kong Hong , Srivatsa Sriram , Tai Victoria , Greenblatt Eli , Holmes Matthew , Riley James L. , June Carl H. , Sheppard Neil C.
Published: November 2023

Figure S7. Pearson correlation, heatmap, and GSEA analysis of Bulk RNA-Seq data
Supplementary Figure 6 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
Authors: Zhang Caimei , Kadu Siddhant , Xiao Yansen , Johnson Omar , Kelly Andre , O'Connor Roddy S. , Lai Meizan , Kong Hong , Srivatsa Sriram , Tai Victoria , Greenblatt Eli , Holmes Matthew , Riley James L. , June Carl H. , Sheppard Neil C.
Published: November 2023

Figure S6. Isoplexis-tSNE plots and polyfunctionality heatmap of single-cell secretome
Supplementary Table 1 from Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy
Authors: Lee Yi-Mei , Hsu Chia-Lang , Chen Yu-Hsin , Ou Da-Liang , Hsu Chiun , Tan Ching-Ting
Published: November 2023

detailed data of WES
Supplementary Figures from Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy
Authors: Lee Yi-Mei , Hsu Chia-Lang , Chen Yu-Hsin , Ou Da-Liang , Hsu Chiun , Tan Ching-Ting
Published: November 2023

Supplementary figures to support the main manuscript.
Supplementary Figure 5 from slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis
Authors: Finotti Giulia , Pietronigro Enrica , Balanzin Camillo , Lonardi Silvia , Constantin Gabriela , Chao Mark P. , Tecchio Cristina , Vermi William , Cassatella Marco A.
Published: November 2023

Control staining for CD19 and MDC8 on human tissue sections.
Supplementary Figure 3 from slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis
Authors: Finotti Giulia , Pietronigro Enrica , Balanzin Camillo , Lonardi Silvia , Constantin Gabriela , Chao Mark P. , Tecchio Cristina , Vermi William , Cassatella Marco A.
Published: November 2023

Confocal and immunofluorescence microscopy images of slan+-monocytes cocultured with Daudi cells.
Supplementary Figure 1 from slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis
Authors: Finotti Giulia , Pietronigro Enrica , Balanzin Camillo , Lonardi Silvia , Constantin Gabriela , Chao Mark P. , Tecchio Cristina , Vermi William , Cassatella Marco A.
Published: November 2023

slan+-monocytes and NK cells require FcγRIII/CD16 engagement for their ADCC, although relying on different killing mechanisms.
Data from Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy
Authors: Lee Yi-Mei , Hsu Chia-Lang , Chen Yu-Hsin , Ou Da-Liang , Hsu Chiun , Tan Ching-Ting
Published: November 2023

Abstract
The immune checkpoint inhibitor (ICI), anti–programmed death-1 (anti–PD-1), has shown moderate efficacy in some patients with head and neck squamous cell carcinoma (HNSCC). Because of this, it is imperative to establish a mouse tumor model to explore mechanisms of antitumor immunity and to develop novel therapeutic options. Here, we examined the 4-nitroquinoline-1-oxide (4NQO)–induced oral squamous cell carcinoma (OSCC) model for genetic aberrations, transcriptomic profiles, and immune cell composition at different pathologic stages. Genomic exome analysis in OSCC-bearing mice showed conservation of critical mutations found in human HNSCC. Transcriptomic data revealed that a key signature comprised of immune-related genes was increased beginning at the moderate dysplasia stages. We first identified that macrophage composition in primary tumors differed across pathologic stages, leading to an oncogenic evolution through a change in the M1/M2 macrophage ratio during tumorigenesis. We treated the 4NQO-induced OSCC-bearing mice with anti–PD-1 and agonistic anti-CD40, which modulated multiple immune responses. The growth of tumor cells was significantly decreased by agonistic anti-CD40 by promoting an increase in the M1/M2 ratio. By examining cross-species genomic conservation in human and mouse tumors, our study demonstrates the molecular mechanisms underlying the development of OSCC and the regulation of contributing immune-related factors, and aims to facilitate the development of suitable ICI-based treatments for patients with HNSCC.
Data from slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis
Authors: Finotti Giulia , Pietronigro Enrica , Balanzin Camillo , Lonardi Silvia , Constantin Gabriela , Chao Mark P. , Tecchio Cristina , Vermi William , Cassatella Marco A.
Published: November 2023

Abstract
Monocytes positive for 6-Sulfo LacNAc (slan) are a major subset of nonclassical CD14dimCD16+ monocytes in humans. We have shown that slan+ cells infiltrate lymphomas and elicit an antibody-dependent cellular cytotoxicity (ADCC) of neoplastic B cells mediated by the anti-CD20 therapeutic rituximab. Herein, by performing blocking experiments and flow cytometry analyses, as well as confocal microscopy and live-cell imaging assays, we extended the findings to other humanized antibodies and deciphered the underlying effector mechanism(s). Specifically, we show that, after coculture with target cells coated with anti-CD20 or anti-CD38, slan+ monocytes mediate trogocytosis, a cell–cell contact dependent, antibody-mediated process that triggers an active, mechanic disruption of target cell membranes. Trogocytosis by slan+ monocytes leads to a necrotic type of target cell death known as trogoptosis, which, once initiated, was partially sustained by endogenous TNFα. We also found that slan+ monocytes, unlike natural killer (NK) cells, mediate a direct ADCC with all types of anti-CD47 analyzed, and this was independent of their IgG isotype. The latter findings unveil a potentially relevant contribution by slan+ monocytes in mediating the therapeutic efficacy of anti-CD47 in clinical practice, which could be particularly important when NK cells are exhausted or deficient in number. Overall, our observations shed new light on the cytotoxic mechanisms exerted by slan+ monocytes in antibody-dependent tumor cell targeting and advance our knowledge on how to expand our therapeutic arsenal for cancer therapy.
Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Authors: Lancman Guido , Parsa Kian , Kotlarz Krzysztof , Avery Lisa , Lurie Alaina , Lieberman-Cribbin Alex , Cho Hearn Jay , Parekh Samir S. , Richard Shambavi , Richter Joshua , Rodriguez Cesar , Rossi Adriana , Sanchez Larysa J. , Thibaud Santiago , Jagannath Sundar , Chari Ajai
Published: November 2023

Anonymized patient-level data. Drug names have been de-identified and will be made available upon request once all of the sponsors have published results from these trials.
Table S9 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Full ex vivo AUC values and clinical annotations
Table S6 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Pairwise feature KW test screen
Table S5 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Ridge regression coefficients
Table S3 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Correlations of cell state gene sig with drug sensitivity
Supplementary Figure S4 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Sensitivity of OCI-AML2 CRISPR/Cas9-KO cell line models to venetoclax or the MDM2 antagonist idasanutlin
Supplementary Figure S3 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Sensitivity and synergy of the Ven+Ruxolitinib combination in AML cell lines
Supplementary Figure S2 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Screening of venetoclax combinations and respective single agents against non-leukemic human stromal and bone marrow mononuclear cells
Supplementary Figure S1 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Authors: Eide Christopher A. , Kurtz Stephen E. , Kaempf Andy , Long Nicola , Joshi Sunil Kumar , Nechiporuk Tamilla , Huang Ariane , Dibb Charles A. , Taylor Akosha , Bottomly Daniel , McWeeney Shannon K. , Minnier Jessica , Lachowiez Curtis A. , Saultz Jennifer N. , Swords Ronan T. , Agarwal Anupriya , Chang Bill H. , Druker Brian J. , Tyner Jeffrey W.
Published: November 2023

Comparison of ex vivo sensitivity to venetoclax combinations with respect to their constituent single-agent drugs.
Supplementary Figures S1-S13 from Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells
Authors: Nelde Annika , Schuster Heiko , Heitmann Jonas S. , Bauer Jens , Maringer Yacine , Zwick Melissa , Volkmer Jens-Peter , Chen James Y. , Stanger Anna M. Paczulla , Lehmann Ariane , Appiah Bismark , Märklin Melanie , Rücker-Braun Elke , Salih Helmut R. , Roerden Malte , Schroeder Sarah M. , Häring Max-Felix , Schlosser Andreas , Schetelig Johannes , Schmitz Marc , Boerries Melanie , Köhler Natalie , Lengerke Claudia , Majeti Ravindra , Weissman Irving L. , Rammensee Hans-Georg , Walz Juliane S.
Published: November 2023

The Supplementary Figures file includes Figures S1 to S13.
Figure S1: Gating strategy for the evaluation of LSC frequencies pre and post enrichment.
Figure S2: Amino acid distribution within LSC and AML bulk immunopeptidomes.
Figure S3: HLA class I immunopeptidomics.
Figure S4: Abundance of AML- and AML/LSC-associated HLA class I ligands within the immunopeptidome.
Figure S5: Identification of AML- and AML/LSC-associated HLA class II antigen targets by comparative immunopeptidome profiling.
Figure S6: Abundance of AML- and AML/LSC-associated HLA class II peptides within the immunopeptidome.
Figure S7: Spectral validation of HLA class I-restricted AML- and AML/LSC-associated peptides.
Figure S8: Spectral validation of HLA class II-restricted AML- and AML/LSC-associated peptides.
Figure S9: Magnitude and functionality of in vitro primed CD8+ T cells.
Figure S10: Characterization of memory T cell responses detected in ELISpot assays.
Figure S11: Further characterization of HLA class II-restricted antigens.
Figure S12: In-depth characterization and phenotyping of HLA class II AML/LSC-specific CD4+ T cells by single-cell RNA sequencing and multi-color flow cytometry.
Figure S13: Impact of immunopeptidome diversity and peptide-specific immune responses on patient survival.
Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Authors: Lancman Guido , Parsa Kian , Kotlarz Krzysztof , Avery Lisa , Lurie Alaina , Lieberman-Cribbin Alex , Cho Hearn Jay , Parekh Samir S. , Richard Shambavi , Richter Joshua , Rodriguez Cesar , Rossi Adriana , Sanchez Larysa J. , Thibaud Santiago , Jagannath Sundar , Chari Ajai
Published: November 2023

Swimmer’s plot for bacterial grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Authors: Lancman Guido , Parsa Kian , Kotlarz Krzysztof , Avery Lisa , Lurie Alaina , Lieberman-Cribbin Alex , Cho Hearn Jay , Parekh Samir S. , Richard Shambavi , Richter Joshua , Rodriguez Cesar , Rossi Adriana , Sanchez Larysa J. , Thibaud Santiago , Jagannath Sundar , Chari Ajai
Published: November 2023

Swimmer’s plot for all grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Authors: Lancman Guido , Parsa Kian , Kotlarz Krzysztof , Avery Lisa , Lurie Alaina , Lieberman-Cribbin Alex , Cho Hearn Jay , Parekh Samir S. , Richard Shambavi , Richter Joshua , Rodriguez Cesar , Rossi Adriana , Sanchez Larysa J. , Thibaud Santiago , Jagannath Sundar , Chari Ajai
Published: November 2023

Absolute lymphocyte counts over time in individual patients
Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Authors: Lancman Guido , Parsa Kian , Kotlarz Krzysztof , Avery Lisa , Lurie Alaina , Lieberman-Cribbin Alex , Cho Hearn Jay , Parekh Samir S. , Richard Shambavi , Richter Joshua , Rodriguez Cesar , Rossi Adriana , Sanchez Larysa J. , Thibaud Santiago , Jagannath Sundar , Chari Ajai
Published: November 2023

Abstract
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.
Significance:
To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.

See related commentary by Garfall and Stadtmauer, p. 427.

This article is featured in Selected Articles from This Issue, p. 419